Literature DB >> 2447123

Antibodies to sulfated glucuronic acid containing glycosphingolipids in neuropathy associated with anti-MAG antibodies and in normal subjects.

S McGinnis1, T Kohriyama, R K Yu, M A Pesce, N Latov.   

Abstract

Serum of patients with neuropathy and IgM monoclonal antibodies (M-proteins) that bind to the myelin-associated glycoprotein (MAG) were tested for binding to the major cross-reactive sulfated glucuronic acid containing glycosphingolipid, sulfated glucuronic acid paragloboside (SGPG). IgM binding to the glycolipid was detectable at serum dilutions of 1:10,000 and reactivity was greatest at 4 degrees C. Low titers of IgM binding to the glycolipid were also detected in sera from normal subjects and from patients with neurologic or rheumatologic diseases without serum M-proteins. Binding activity was present in 25% of the sera tested, and titers ranged between 1:25 and 1:400. One patient with peripheral neuropathy, however, had a measurable titer of 1:12,800 in the absence of monoclonal gammopathy. The study indicates that cold reacting anti-SGPG IgM antibodies are frequent constituents of the normal human antibody repertoire, and that monoclonal or polyclonal expansion of B cells that secrete these antibodies, is associated with peripheral neuropathy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2447123     DOI: 10.1016/0165-5728(88)90019-7

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

1.  CD5 expression on B cells may be an activation marker for secretion of anti-myelin antibodies in patients with polyneuropathy associated with monoclonal gammopathy.

Authors:  C Ekerfelt; J Ernerudh; G Solders; M Vrethem
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

Review 2.  Diagnosis and treatment of chronic acquired demyelinating polyneuropathies.

Authors:  Norman Latov
Journal:  Nat Rev Neurol       Date:  2014-07-01       Impact factor: 42.937

Review 3.  Gangliosides and glycosphingolipids of peripheral nervous system myelins--a minireview.

Authors:  K Ogawa-Goto; T Abe
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

4.  Reactivity of human monoclonal IgM with nerve glycosphingolipids.

Authors:  B Hauttecoeur; C Schmitt; C Dubois; F Danon; J C Brouet
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

5.  Peripheral neuropathy associated with monoclonal IgM antibody to glycolipids with a terminal glucuronyl-3-sulfate epitope.

Authors:  P Fredman; J Lycke; O Andersen; M Vrethem; J Ernerudh; L Svennerholm
Journal:  J Neurol       Date:  1993-06       Impact factor: 4.849

6.  Anti-sulphatide antibodies in peripheral neuropathy.

Authors:  L H van den Berg; C L Lankamp; A E de Jager; N C Notermans; P Sodaar; J Marrink; H J de Jong; P R Bär; J H Wokke
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-11       Impact factor: 10.154

7.  Immunoglobulin (Ig) M antibody against myelin associated glycoprotein (MAG): A comparison of methods.

Authors:  T D Jaskowski; T B Martins; C M Litwin; H R Hill
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

8.  Immunochemical and clinical effects of immunosuppressive treatment in monoclonal IgM neuropathy.

Authors:  J H Ernerudh; M Vrethem; O Andersen; C Lindberg; G Berlin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

9.  Autoantibodies against Forssman glycolipids in Graves' disease and Hashimoto's thyroiditis.

Authors:  T Ariga; T Yoshida; T Mimori; R K Yu
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

10.  Monoclonal IgM from patients with peripheral demyelinating neuropathies cross-react with bacterial polypeptides.

Authors:  J C Brouet; X Mariette; M C Gendron; M L Dubreuil
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.